IceCure Medical Ltd. (NASDAQ: ICCM) shares surged 280.75% to $8.11 on Wednesday following the company's report of a 70% increase in its U.S. active commercial install base for the ProSense breast cancer cryoablation system. The growth, occurring after U.S. Food and Drug Administration (FDA) marketing authorization in October 2025, reflects accelerating commercial adoption, expanding physician demand, and continued expansion of the Company's U.S. footprint. Despite the rally, the stock remains in a broader downward trend, trading below key long-term moving averages.

Adoption and Market Penetration

As adoption expands, ProSense breast cancer cryoablation procedures have been performed in major metropolitan areas throughout the country, including Los Angeles, New York, Atlanta, Dallas, Detroit, Philadelphia, Phoenix, and Memphis. The Company had strong engagement at two leading breast health conferences held earlier this year: the Society of Breast Imaging (SBI) Annual Symposium and the American Society of Breast Surgeons (ASBrS) Annual Meeting. IceCure generated significantly more sales leads for ProSense systems at these events compared to the same conferences in 2025, prior to FDA authorization.

Drivers of Demand

Several factors are driving the increased demand for ProSense systems:

• Growing Clinical Acceptance: ASBrS recently updated its Resource Guide to recommend cryoablation as a local treatment option for low-risk breast cancer patients.
• Increasing Patient Awareness: ProSense has received broader media attention, including coverage by Reuters and local television news segments aired across approximately 190 CBS and CW-affiliated stations nationwide.

Executive Commentary

"With growing physician interest, expanding clinical acceptance, and increased patient awareness, we believe we remain in the early stages of a significant commercial opportunity for breast cancer cryoablation in the U.S.," said IceCure's Chief Executive Officer, Eyal Shamir. "We are focused on continuing to expand our installed base, supporting physicians with training and education and increasing access to ProSense for eligible patients."

Technical Analysis

IceCure remains in a broader downward trend even after the latest surge. The stock trades about 12.9% below the 50-day simple moving average at $7.29, roughly 48.2% below the 100-day simple moving average at $12.25, and close to 65% below the 200-day simple moving average at $18.14. In the short term, IceCure sits about 30% above the 20-day simple moving average at $4.89. The Relative Strength Index (RSI) is at 21.02, placing the stock in oversold territory. Key resistance is noted at $7.50.

About ProSense

The ProSense Cryoablation System is the first and only medical device to receive FDA marketing authorization for the local treatment of low-risk breast cancer with adjuvant endocrine therapy for women aged 70 and above, including patients who are not suitable for surgical alternatives. The system uses liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.